Portolan Capital Management LLC Buys 218,901 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Portolan Capital Management LLC boosted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 201.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 327,764 shares of the company’s stock after buying an additional 218,901 shares during the quarter. Amphastar Pharmaceuticals makes up about 1.2% of Portolan Capital Management LLC’s investment portfolio, making the stock its 23rd largest holding. Portolan Capital Management LLC’s holdings in Amphastar Pharmaceuticals were worth $15,906,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in AMPH. GAMMA Investing LLC grew its position in Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after buying an additional 273 shares during the period. Innealta Capital LLC bought a new stake in Amphastar Pharmaceuticals during the second quarter valued at approximately $55,000. Point72 Asia Singapore Pte. Ltd. grew its position in Amphastar Pharmaceuticals by 53.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock valued at $56,000 after buying an additional 398 shares during the period. Blue Trust Inc. grew its position in Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after buying an additional 309 shares during the period. Finally, Asset Management One Co. Ltd. bought a new stake in Amphastar Pharmaceuticals during the third quarter valued at approximately $78,000. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $44.92 on Wednesday. The company has a market cap of $2.16 billion, a price-to-earnings ratio of 14.97, a PEG ratio of 0.91 and a beta of 0.78. The firm’s fifty day moving average is $47.73 and its 200 day moving average is $44.60. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 52-week low of $36.56 and a 52-week high of $65.92.

Analyst Upgrades and Downgrades

AMPH has been the topic of several analyst reports. Piper Sandler lowered their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Finally, Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 target price on the stock. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $60.33.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Yakob Liawatidewi sold 5,214 shares of the business’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $271,388.70. Following the transaction, the executive vice president now owns 74,938 shares in the company, valued at $3,900,522.90. The trade was a 6.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Rong Zhou sold 6,893 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $48.88, for a total transaction of $336,929.84. Following the transaction, the executive vice president now owns 118,388 shares in the company, valued at $5,786,805.44. This trade represents a 5.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,533 shares of company stock valued at $1,378,252 over the last 90 days. 27.10% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.